Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients

Fouad Albaaj, Alastair J. Hutchison

    Research output: Contribution to journalArticlepeer-review


    Hyperphosphataemia is a usual accompaniment of end stage renal disease and dialysis, in the absence of dietary phosphate restriction or supplemental phosphate binders. It is associated with renal osteodystrophy, metastatic calcification and increased mortality and morbidity. Despite dietary restriction and dialysis, most patients will require a phosphate-binding agent to treat this condition. However, phosphate control has not significantly improved over the last two decades, mainly because of the lack of an ideal oral phosphate-binding agent. Aluminium- and calcium-based agents are associated with major side effects, despite their undoubted efficacy. Although sevelamer hydrochloride represents a step forward in the management of hyperphosphataemia, it is not an ideal phosphate binder due to its cost and tablet burden. Lanthanum carbonate is the most recent non-calcium, non-aluminium, phosphate-binding agent. It is effective and well-tolerated, and no negative effects on bone histology have been observed. © 2005 Ashley Publications Ltd.
    Original languageEnglish
    Pages (from-to)319-328
    Number of pages9
    JournalExpert opinion on pharmacotherapy
    Issue number2
    Publication statusPublished - Feb 2005


    • Chronic renal failure
    • End stage renal disease
    • Hyperphosphataemia
    • Renal osteodystrophy


    Dive into the research topics of 'Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients'. Together they form a unique fingerprint.

    Cite this